A new lymphoblastoid cell line, DG-75, was investigated for its ability to produce interferon. DG-75 cells, previously shown to be free of Epstein-Barr virus genome and receptors, could be grown in submerged culture and could produce interferon in titers comparable to interferon produced by Namalva cells. The interferon produced was similar in size to the Namalva interferon as determined by gel filtration in Ultrogel AcA54. The DG-75 cells present a new source for large quantities of interferon which may be safer for human use than the Namalva interferon.
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The recent growing use of interferons (IFNs) in clinical trials as antiviral and antitumor agents (5, 16, 18) has resulted in an increased demand for human IFNs. Current methods for the production of IFNs by either viral induction of human peripheral blood leukocytes (3) or superinduction of monolayer cultures of human diploid cell strains (7) are difficult and expensive and do not provide the quantities ofIFNs needed for extensive therapeutic trials in humans. The successful transfer of human IFN genes into Escherichia coli (14) constitutes a new source for mass production of human IFN. However, the methodology for obtaining large amounts of highly purified, high-titered bacterial IFN is still to be developed. Lymphoblastoid cell lines constitute another source for large quantities of IFN (19) . These cells can be grown in submerged cultures which can be easily scaled-up and provide large quantities of human IFN. The Namalva lymphoblastoid cell line, established by Klein et al. (11) , is widely used as a cell substrate for the production of human lymphoblastoid IFN after viral induction. Since the Namalva cells contain parts of the Epstein-Barr virus genome, they are not presently accepted in many countries as IFN producers for clinical trials in humans.
In RESULTS AND DISCUSSION Kinetics of DG-75 cell growth. The growth characteristics of DG-75 cells were studied to determine conditions yielding mimum cell production. RPMI 1640 medium was found to be superior to both minimal essential medium and McCoy 5A medium. Ten percent fetal bovine serum was optimal for ceil growth. Every 2 to 3 days, the cell culture was diluted to 5 x 105 cells per ml in fresh medium. Under these conditions the saturation density of the culture reached 2 x 106 to 3 x 10' viable cells per ml (over 95% viability). When new cultures were established in fresh medium, a 1-to 2-day lag period in growth was observed. At the log phase, a doubling time of 24 h was obtained. Agitation of the culture was necessary to achieve optimal cell growth. Poor growth was observed when cultures were kept stationary. The growth characteristics of the DG-75 cells were found to be similar to those of the Namalva cells, as previously reported by our group (17) and by Zoon et al. (21) .
IFN production by DG-75 cells. The kinetics of IFN production by DG-75 cells were studied, with Newcastle disease virus and Sendai virus as inducers. In both cases IFN was detected at 5 h after initiation of induction. By 10 h maxum levels of 30,000 to 50,000 IFN units per ml were obtained. No significant changes in IFN titers were observed when induced cultures were assayed at 24 or 48 h. The kinetics of DG-75 IFN production and the titers achieved were similar to those obtained by Namalva cells in our laboratory and by other groups (9, 21) .
The IFN yield was independent of serum concentration. No significant differences in IFN titers were observed in cultures containing serum ranging from 0 to 10%. In this feature too, the DG-75 IFN resemble Namalva IFN (9) . The stability of crude DG-75 IFN in a frozen state at -70°C was tested for up to 3 months. No significant changes in IFN titers were observed. The consistency of IFN production by celLs was studied over a period of 20 weeks in comparison with IFN produced by Namalva cells. There was a difference of more than 10- fold between the highest and the lowest IFN titers obtained over this period (Fig. 1) . DG-75 and Namalva cells did not differ significantly in this respect. In early studies, when low-passaged DG-75 celLs were used, IFN production in some cases dropped to zero for no known reason. This phenomenon was not observed when later-pas- saged cells were used.
Gel filtration of DG-75 and Namalva IFNs. Gel filtration of trichloroacetic acid-concentrated crude IFN obtained from DG-75 and Namalva cells was performed in Ultrogel AcA54 columns (Fig. 2) . When the filtration was run under the same conditions, DG-75 and Namalva IFNs showed similar profiles, and IFN was collected at the same fractions. The recovery was 80 to 90%. Crude as well as partially purified DG-75 IFN were assayed on Madin-Darby bovine kidney and human fibroblast cells. IFN titers were comparable on both cells, indicating a full cross-reactivity, classifying this IFN in the a group (6) .
The results reported in this paper present a new, human lymphoblastoid cell line, free of Epstein-Barr virus genome and receptors. The DG-75 cells can be grown successfully in submerged cultures and produce high titers of IFN 
